RLFTF — MindMaze Therapeutics Holding SA
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1854078 ·
Switzerland
Last close
$0.25
Market Cap
$3.21M
52W High
$0.59
52W Low
$0.21
ADV30
4,177
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2025 | — | — | — | — | 47,987,000 | 12,500,000 | 15,354,000 |
| Dec 2024 | — | — | — | — | 53,224,000 | 15,080,000 | 16,560,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-240,222,000
Inventory
$923,000
Receivables
$1,468,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$642,000
EBITDA
$-9,143,000
Free Cash Flow
—
Enterprise Value
—
Total Cash
—
Total Debt
—
Shares Out
12,591,919
Trailing EPS
$-1.70
Book Value
$0.31
ROE
-51.6%
ROA
-25.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 8,417,000 | -7,906,000 | -17,119,000 | 53,224,000 | 16,560,000 | — | -2,916,000 |
| Dec 2023 | 6,033,000 | -19,778,000 | -98,181,000 | 76,390,000 | 24,162,000 | — | -17,612,000 |
| Dec 2022 | 6,081,000 | -35,474,000 | -50,790,000 | 188,798,000 | 43,381,000 | — | -24,126,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DCOY | Decoy Therapeutics Inc. | $3.14M | $5.91 | — |
| PMHS | Polomar Health Services, Inc. | $3.31M | $0.12 | — |
| UPC | Universe Pharmaceuticals INC | $3.33M | $5.27 | — |
| GRI | GRI Bio, Inc. | $3.08M | $1.74 | — |
| SBFM | Sunshine Biopharma Inc. | $3.38M | $2.09 | — |
News headlines (Yahoo Finance, 1h cache)
MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy
2026-07-09 05:35 · Yahoo
MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe
2026-07-01 05:22 · Yahoo
MindMaze Therapeutics Announces Results of Annual General Meeting
2026-06-25 20:32 · Yahoo
MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting
2026-06-03 05:00 · Yahoo
MindMaze Therapeutics Announces Non-Core Asset Sale and Organizational Simplification
2026-06-02 05:05 · Yahoo
MindMaze Therapeutics Announces CHF 8.0 Million Strategic Equity Financing
2026-05-26 05:50 · Yahoo
MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S.
2026-05-12 05:25 · Yahoo
MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank
2026-03-19 06:35 · Yahoo
MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale
2026-03-12 06:30 · Yahoo
MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation
2026-03-03 07:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.